The announcement of a takeover gave Gerresheimer s shares, which had been flagging recently, a boost on Thursday. They recovered by 12 percent in the morning from their three-month low reached the day.
Analyst Olivier Calvet from UBS research considers the stock attractive and recommends it with a Buy rating. The target price continues to be set at EUR 145.
The major Swiss bank UBS has lowered its target price for Schott Pharma from 40 to 33 euros, but left its rating at Neutral. Analyst Olivier Calvet adjusted his valuation model to the weaker outlook.